MA48464A - N-ACETYLATED AND NON-ACETYLATED DIPEPTIDES CONTAINING ARGININE FOR REDUCING THE VISCOSITY OF VISCOUS COMPOSITIONS OF THERAPEUTIC POLYPEPTIDES - Google Patents
N-ACETYLATED AND NON-ACETYLATED DIPEPTIDES CONTAINING ARGININE FOR REDUCING THE VISCOSITY OF VISCOUS COMPOSITIONS OF THERAPEUTIC POLYPEPTIDESInfo
- Publication number
- MA48464A MA48464A MA048464A MA48464A MA48464A MA 48464 A MA48464 A MA 48464A MA 048464 A MA048464 A MA 048464A MA 48464 A MA48464 A MA 48464A MA 48464 A MA48464 A MA 48464A
- Authority
- MA
- Morocco
- Prior art keywords
- acetylated
- viscosity
- reducing
- therapeutic polypeptides
- viscous compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762492020P | 2017-04-28 | 2017-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA48464A true MA48464A (en) | 2020-03-04 |
Family
ID=62165708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA048464A MA48464A (en) | 2017-04-28 | 2018-04-27 | N-ACETYLATED AND NON-ACETYLATED DIPEPTIDES CONTAINING ARGININE FOR REDUCING THE VISCOSITY OF VISCOUS COMPOSITIONS OF THERAPEUTIC POLYPEPTIDES |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12103979B2 (en) |
| EP (1) | EP3615069B1 (en) |
| AU (1) | AU2018258676B2 (en) |
| CA (1) | CA3279830A1 (en) |
| ES (1) | ES3036143T3 (en) |
| MA (1) | MA48464A (en) |
| WO (1) | WO2018201064A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI856084B (en) * | 2019-04-01 | 2024-09-21 | 美商建南德克公司 | Compositions and methods for stabilizing protein-containing formulations |
| CN113660927A (en) * | 2019-04-23 | 2021-11-16 | 安进公司 | Viscosity reduction of high concentration protein formulations using low molecular weight polyvinylpyrrolidone (PVP) |
| US20230242655A1 (en) | 2019-12-03 | 2023-08-03 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| WO2021243298A1 (en) * | 2020-05-29 | 2021-12-02 | Chinook Therapeutics, Inc. | Methods of treating iga nephropathy with an april binding antibody |
| EP4238578A4 (en) * | 2020-10-30 | 2024-09-11 | Eisai R&D Management Co., Ltd. | PHARMACEUTICAL COMPOSITION |
| US20220193238A1 (en) * | 2020-12-17 | 2022-06-23 | Astrazeneca Ab | Anti-il5r antibody formulations |
| EP4302778A4 (en) * | 2021-03-03 | 2025-03-12 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pharmaceutical composition containing anti-tslp antibody |
| US20240343795A1 (en) * | 2021-08-12 | 2024-10-17 | Amgen Inc. | Antibody formulations |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69120146T2 (en) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | GENERATION OF XENOGENIC ANTIBODIES |
| US6767892B1 (en) | 1997-11-07 | 2004-07-27 | Chrion Corporation | Compositions providing for increased IGF-I solubility |
| RS51829B (en) | 2001-08-23 | 2012-02-29 | Genmab A/S. | HUMAN ANTIBODIES SPECIFIC TO INTERLEUKIN 15 (IL-15) |
| US7906625B2 (en) | 2005-01-24 | 2011-03-15 | Amgen Inc. | Humanized anti-amyloid antibody |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| WO2008154014A2 (en) | 2007-06-11 | 2008-12-18 | Amgen Inc. | A method for culturing mammalian cells to improve recombinant protein production |
| CN102027012A (en) | 2007-06-20 | 2011-04-20 | Irm责任有限公司 | Methods and compositions for treating allergic diseases |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| TWI516501B (en) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9 antagonists |
| BR112012027828A2 (en) * | 2010-05-03 | 2016-08-09 | Genentech Inc | matter composition, article of manufacture and method of reducing the viscosity of a protein containing formulation and preparing an aqueous protein containing formulation |
| WO2015196091A1 (en) * | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| AU2015289874A1 (en) | 2014-07-14 | 2017-02-02 | Amgen Inc. | Crystalline antibody formulations |
| WO2016065181A1 (en) * | 2014-10-23 | 2016-04-28 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
-
2018
- 2018-04-27 WO PCT/US2018/029981 patent/WO2018201064A1/en not_active Ceased
- 2018-04-27 US US16/607,673 patent/US12103979B2/en active Active
- 2018-04-27 ES ES18724732T patent/ES3036143T3/en active Active
- 2018-04-27 AU AU2018258676A patent/AU2018258676B2/en active Active
- 2018-04-27 EP EP18724732.5A patent/EP3615069B1/en active Active
- 2018-04-27 CA CA3279830A patent/CA3279830A1/en active Pending
- 2018-04-27 MA MA048464A patent/MA48464A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018201064A1 (en) | 2018-11-01 |
| ES3036143T3 (en) | 2025-09-15 |
| AU2018258676A1 (en) | 2019-10-31 |
| EP3615069B1 (en) | 2025-05-28 |
| CA3279830A1 (en) | 2026-03-02 |
| AU2018258676B2 (en) | 2024-09-19 |
| US12103979B2 (en) | 2024-10-01 |
| US20200048367A1 (en) | 2020-02-13 |
| CA3059369A1 (en) | 2018-11-01 |
| EP3615069A1 (en) | 2020-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA48464A (en) | N-ACETYLATED AND NON-ACETYLATED DIPEPTIDES CONTAINING ARGININE FOR REDUCING THE VISCOSITY OF VISCOUS COMPOSITIONS OF THERAPEUTIC POLYPEPTIDES | |
| MA51796A (en) | METHODS AND COMPOSITIONS FOR THE ADMINISTRATION OF THERAPEUTIC PROTEINS | |
| EP3880717A4 (en) | COMPOSITIONS AND METHODS OF DELIVERING CRISPR/CAS-EFFECTING POLYPEPTIDES | |
| EP3880688A4 (en) | PREPARATIONS AND COMPOSITIONS OF OLIGOSACCHARIDES | |
| PL3717471T3 (en) | NEW COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF DISEASES | |
| MA47688A (en) | USEFUL COMPOSITIONS IN THE TREATMENT OF SPINAL AMYOTROPHY | |
| EP3427601A4 (en) | COMPOSITION OF SYRUP CONTAINING ALLULOSE AND FOOD CONTAINING THE SAME | |
| MA45688A (en) | COMPOSITIONS AND METHODS FOR THE POTENTIALIZATION OF ANTIMICROBIAL AGENTS | |
| EP3412660A4 (en) | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | |
| EP3777866A4 (en) | PHARMACEUTICAL COMPOSITION AND APPLICATION OF THE LATTER | |
| EP3413887A4 (en) | INTERMEDIATES USED IN THE SYNTHESIS OF ÉRIBULINE AND ASSOCIATED METHODS OF SYNTHESIS | |
| SG11202009574RA (en) | Combinations of osteopontin and 2'-fucosyllactose for use as medicaments | |
| PL3810128T3 (en) | COMPOSITIONS FOR THE TREATMENT AND/OR PREVENTION OF PROTEIN AGGREGATION DISEASES | |
| IT201700085412A1 (en) | Composition for use in the prevention and treatment of cardiovascular diseases | |
| EP3785698A4 (en) | PHARMACEUTICAL COMPOSITION OF EDARAVONE | |
| EP3679863A4 (en) | SEALANT SYRINGE SET | |
| EP3648773A4 (en) | COMPOUNDS AND METHODS FOR THE TRANSMEMBRANARY ADMINISTRATION OF MOLECULES | |
| EP3817750A4 (en) | COMPOSITIONS OF CANNABIDIOL ASSOCIATIONS | |
| MA49524A (en) | NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF DEPRESSION | |
| EP3484434A4 (en) | OIL-IN-WATER FOAMS CONTAINING BETULIN AND COMPOSITIONS THEREOF | |
| EP3675858A4 (en) | COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF IRE1 | |
| EP3542821A4 (en) | MOLECULE INDUCING THE DEGRADATION OF p53 AND PHARMACEUTICAL COMPOSITION | |
| EP3638277A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITION OF BETA-SECRETASE | |
| EP3255113C0 (en) | ADHESIVE AND/OR SEALANT COMPOUND | |
| EP3756700A4 (en) | COMPOSITION OF LIQUID EMBOLIC AGENT |